Chemours Company (The) (NYSE:CC) had its price target hoisted by Citigroup Inc. to $59.00 in a research note issued to investors on Friday morning, The Fly reports. Citigroup Inc. currently has a buy rating on the specialty chemicals company’s stock.

Several other brokerages also recently commented on CC. UBS AG reiterated a sell rating and issued a $36.00 target price (up previously from $35.00) on shares of Chemours Company (The) in a report on Wednesday, June 14th. Jefferies Group LLC increased their price target on shares of Chemours Company (The) to $60.00 and gave the company a buy rating in a research report on Thursday, August 3rd. BidaskClub upgraded shares of Chemours Company (The) from a hold rating to a buy rating in a research report on Wednesday, July 12th. J P Morgan Chase & Co upgraded shares of Chemours Company (The) from a neutral rating to an overweight rating and increased their target price for the stock from $39.00 to $50.00 in a research report on Friday, May 12th. Finally, Zacks Investment Research upgraded shares of Chemours Company (The) from a hold rating to a strong-buy rating and set a $51.00 target price for the company in a research report on Friday, July 14th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Chemours Company (The) currently has a consensus rating of Buy and a consensus target price of $46.25.

Shares of Chemours Company (NYSE:CC) opened at 49.77 on Friday. The firm has a market capitalization of $9.21 billion, a price-to-earnings ratio of 32.55 and a beta of 3.63. Chemours Company has a 12-month low of $8.86 and a 12-month high of $51.51. The firm has a 50-day moving average of $41.37 and a 200 day moving average of $37.03.

Chemours Company (The) (NYSE:CC) last issued its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.02. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. Chemours Company (The)’s revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.27 earnings per share. On average, equities research analysts expect that Chemours Company will post $3.51 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Chemours Company (The) (CC) Price Target Raised to $59.00” was reported by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/08/chemours-company-the-cc-price-target-raised-to-59-00.html.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 17th will be given a $0.03 dividend. This represents a $0.12 annualized dividend and a dividend yield of 0.24%. The ex-dividend date of this dividend is Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is presently 8.11%.

In other Chemours Company (The) news, VP Erich Parker sold 4,908 shares of the business’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total value of $223,461.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul Kirsch sold 19,036 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $41.42, for a total value of $788,471.12. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in CC. Financial Architects Inc increased its position in shares of Chemours Company (The) by 1,230.3% in the second quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock worth $111,000 after buying an additional 2,719 shares during the period. Benjamin F. Edwards & Company Inc. increased its position in Chemours Company (The) by 2,138.8% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock valued at $118,000 after buying an additional 2,973 shares during the last quarter. Ropes Wealth Advisors LLC increased its position in Chemours Company (The) by 82.4% in the first quarter. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock valued at $119,000 after buying an additional 1,400 shares during the last quarter. Schroder Investment Management Group acquired a new position in Chemours Company (The) during the first quarter valued at $156,000. Finally, Cypress Capital Management LLC WY increased its position in Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock valued at $162,000 after buying an additional 80 shares during the last quarter. 75.21% of the stock is owned by hedge funds and other institutional investors.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

The Fly

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.